Start typing to see results...

Home
>
Stock Market
>
>
Zydus Lifesciences Ltd

Zydus Lifesciences Ltd share price and stock overview

Q: What is the NSE symbol and BSE code for Zydus Lifesciences Ltd?

Zydus Lifesciences Ltd trades on NSE under the symbol ZYDUSLIFE and on BSE under code 532321. The ISIN is INE010B01027 and the face value is Rs 1.

Zydus Lifesciences Ltd (NSE: ZYDUSLIFE, BSE: 532321) operates in the Pharmaceuticals - Indian - Bulk Drugs & Formln sector. The stock has an ISIN of INE010B01027 and a face value of Rs 1. As of 04 July 2026, it trades at Rs (1,140.60) with a market capitalisation of Rs 114811.3 crore. Figures are live and subject to change.

Zydus Lifesciences Ltd

Pharmaceuticals - Indian - Bulk Drugs & Formln

NSE BSE

1,140.60 40.80 (3.71%)

As on: 04-Jul-2026 , 08:43 PM

Market Cap(₹Cr) 114811.3

Book Value(₹Cr) 235.2506836

BSE Code : 532321 NSE Symbol : ZYDUSLIFE EPS(TTM) : 36.7 ISIN Demat : INE010B01027 P/E(TTM) : 31.09 Face Value(₹) : 1 Div & Yield % : 0.09

Today Market

Stock Performance

Today Market

Today's High

78,157.52

Todday's Low

77,710.01

Open at

78,152.34

Previous Close

77,502.12

Volumes

Avg Price

261.79

Historical Performance

News

03 Jul 26

Zydus partners with Guardant Health and Apollo Hospitals to introduce Shield' MCD in India

Zydus Lifesciences and Guardant Health, Inc., a leading precision oncology company, have an exclusive agreement to make the Shield' Multi-Cancer Detection (MCD) test available in India, for which Zydus has signed a Memorandum of Understanding (MoU) with Apollo Hospitals to offer the test in the territory.

03 Jul 26

Zydus life rises after signing MoU with Apollo Hospitals to launch Shield cancer detection test

Shares of Apollo Hospitals Enterprise also gained 1.73% to Rs 8,848 on the BSE. Under an exclusive agreement with Zydus Lifesciences, Guardant Health will commercialise the Shield MCD test in India, while Apollo Hospitals will offer the test through its healthcare network.

26 Jun 26

Zydus Lifesciences enters into JV with Sunshine Healthcare

Zydus Lifesciences and Sunshine Healthcare today announced the setting up of a strategic joint venture company ' Zydus Sunshine Lifesciences, with an investment commitment of over USD 20 million to establish a pharmaceutical manufacturing facility in Sri Lanka, strengthening local production and reducing import dependence.

03 Jun 26

Zydus receives warning letter from USFDA for its Baddi site

Zydus Lifesciences has received a Warning Letter from the United States Food and Drug Administration (USFDA) relating to its formula on manufacturing facility located at Baddi, Himachal Pradesh.

Historical Prices

Share Price Chart

Historical Share Price

Date	Open Price (₹)	High Price(₹)	Low Price(₹)	Close Price(₹)	Total Volume	No of Trades	Net Turnover(₹)	NIFTY
03-07-26	1105.00	1142.90	1104.10	1140.60	1862016	50897	2102426999.00	24270.85
02-07-26	1114.10	1114.80	1095.10	1099.80	586078	24360	645266081.40	24175.70
01-07-26	1112.90	1125.90	1105.50	1109.20	1005311	27994	1118728704.00	24005.85
30-06-26	1122.20	1128.50	1110.00	1112.60	1698514	44641	1899811565.50	23865.75
29-06-26	1104.70	1125.30	1099.00	1121.30	1976891	59911	2210662950.10	23946.25
25-06-26	1100.00	1113.30	1096.30	1101.40	1182386	31446	1303896848.90	24056.00
24-06-26	1120.40	1126.00	1095.90	1099.30	1490617	36700	1651875978.90	24021.65
23-06-26	1094.00	1124.50	1087.30	1112.20	2429505	57487	2696693657.00	23824.10
22-06-26	1070.50	1088.20	1064.60	1085.50	1104733	29473	1192004126.20	24102.90
19-06-26	1074.40	1083.00	1065.00	1070.80	887232	20534	951244913.30	24013.10

12 3 ...

Fundamentals

Company Valuation

Market Cap (₹cr)

114811.3

PE Ratio

31.09

PB Ratio

4.85

Dividend Yield

0.09

ROE

31.29

ROCE

30.47

Book Value (₹)

235.2506836

Face Value (₹)

Share Holding Pattern

Category of Shareholder	No of Shares	% Share Holdings	Demat Shares	Share Holders

Promoter & Group

Foreign

Foreign (Promoter & Group) - Bodies Corporate	0	0	0
Foreign (Promoter & Group)-Individuals (Non-Resident / Foreign)	10000	10000	1
Foreign Promoter(Institutional)	0	0	0
Promoter Others	0	0	0

Sub Total

10000

0.00

10000

Indian

Bodies Corporate-Indian (Promoter & Group)	17581	0.00	17581	1
Government(Central / State)-Indian (Promoter & Group)	0	0.00	0	0
Directors & their Relatives-Indian (Promoter & Group)	0	0.00	0	0
Financial Institutions / Banks-Indian (Promoter & Group)	0	0.00	0	0
Individuals / Hindu Undivided Family-Indian (Promoter & Group)	267640	0.03	267640	9
Partnership Firms-Indian (Promoter & Group)	0	0.00	0	0
Persons Acting in Concert	0	0.00	0	0
Trusts	747978452	74.99	747978452	2
Others	0	0.00	0	0

Sub Total

748263673

75.01

748263673

Total ShareHolding for Promoter & Group

748273673

75.01

748273673

Publice Share Holding

Institution

Government(Central / State)	17517	0.00	17517	3
Clearing Members	0	0.00	0	0
Corporate Bodies	0	0.00	0	0
Foreign Direct Investments	0	0.00	0	0
Financial Institutions / Banks	20594	0.00	18284	4
Foreign Bank	0	0.00	0	0
Foreign Bodies Corporate/OCBs/FBC	0	0.00	0	0
Foreign Collaborators	0	0.00	0	0
Foreign Institutional Investors	68751104	6.89	68751104	631
Foreign Venture Capital Investors	0	0.00	0	0
Foreign Institution Other	0	0.00	0	0
Insurance Companies	60595204	6.07	60595204	17
Mutual Funds / UTI	49059440	4.92	49059440	37
Individuals (Non-Resident / Foreign)	0	0.00	0	0
NSDL Intransit	0	0.00	0	0
Others	1955682	0.20	1955682	19
Trusts	0	0.00	0	0
Venture Capital Funds	0	0.00	0	0

Sub total

180399541

18.09

180397231

711

Non Institution

Bodies Corporate	6495066	0.65	6495066	976
Clearing Members	216119	0.02	216119	55
Directors & their Relatives	376693	0.04	376693	6
Employees	0	0.00	0	0
Escrow Account	0	0.00	0	0
Foreign Corporate Bodies	0	0.00	0	0
Foreign Direct Investments	0	0.00	0	0
NRIs/Foreign Individuals/Foreign Nationals	3412594	0.34	3405769	10182
Foreign Non Institution Other	0	0.00	0	0
Hindu Undivided Families	1517506	0.15	1516756	5330
Indian Public	0	0.00	0	0
Individuals holding nominal share capital in excess of Rs. 1 lakh	7375146	0.74	7375146	6
Individuals holding nominal share capital up to Rs. 1 lakh	47101469	4.72	45949224	386479
Market Maker	0	0.00	0	0
NSDL Transit	0	0.00	0	0
Shares in transit	0	0.00	0	0
Societies	0	0.00	0	0
Trust & Foundation	196910	0.02	196910	18
Others	1694604	0.17	1694604	2

Sub Total

68830618

6.90

67670798

403165

Total Public Shareholding

249230159

24.99

248068029

403876

Total of Promoter & Public ShareHolding

997503832

100.00

996341702

403889

Shares held by Custodians and against which Depository Receipts have been issued

ADR	0	0.00	0	0
GDR	0	0.00	0	0
Other Custodians	0	0.00	0	0

Total Shares held by Custodians and against which Depository Receipts have been issued

0.00

Grand Total

997503832

100.00

996341702

403889

Financials (₹ in cr)

Consolidated Standalone

Year End	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Net Sales	23,241.50	19,547.40	17,237.40	15,265.20	15,102.20
OPM (%)	26.88	24.67	18.53	17.85	16.49
OP	6,246.30	4,823.10	3,193.90	2,725.40	2,489.90
Other Income	269.50	284.10	186.60	224.70	37.20
PBIDT	7,108.40	5,654.20	3,442.30	3,678.10	3,173.10
INTEREST	165.90	81.20	129.90	127.00	163.50
PBDT	6,942.50	5,573.00	3,312.40	3,551.10	3,009.60
PBT	5,807.10	4,794.70	1,985.50	2,950.80	2,079.70
EO	-219.60	-14.20	-604.20	112.70	-205.10
PBT after EO	6,026.70	4,808.90	2,589.70	2,838.10	2,284.80
TAXES	1,411.90	977.50	587.80	511.70	147.20
PAT	4,525.50	3,859.50	1,960.30	4,487.30	2,133.60
EPS	44.97	38.14	19.30	43.83	20.84
Raw Material	18.82	23.43	23.92	26.48	25.75
Power and Fuel	1.62	1.97	2.10	2.06	1.65
Employee Cost	15.84	16.05	16.04	15.95	16.49
Other Manufacturing Expenses	0.00	0.00	0.00	0.00	0.00
Selling and Administration Expenses	16.49	14.56	15.65	14.48	15.20
Miscellaneous Expenses	5.81	5.31	4.47	6.04	6.44
Revenue (Growth %)	18.90	13.40	12.92	1.08	5.96
PBIDT (Growth %)	25.72	64.26	-6.41	15.92	25.24
PAT (Growth %)	17.26	96.88	-56.31	110.32	81.34
PBIDT (Margin %)	30.58	28.93	19.97	24.09	21.01
PAT (Margin %)	19.47	19.74	11.37	29.40	14.13

Balance Sheet (₹ in cr)

Particulars (Sources Of Funds)	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Share Capital	100.60	100.60	101.20	102.40	102.40	102.40
Reserves Total	21089.50	15615.90	13538.20	13138.10	12642.10	11157.80
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	21190.10	15716.50	13639.40	13240.50	12744.50	11260.20
Secured Loans	2149.50	0.00	0.00	1005.50	994.40	356.90
Unsecured Loans	6192.70	6178.30	4825.30	1659.20	2925.50	3337.80
Total Debt	8342.20	6178.30	4825.30	2664.70	3919.90	3694.70
Other Liabilities	265.60	209.70	166.20	191.30	179.20	132.70
Total Liabilities	29797.90	22104.50	18630.90	16096.50	16843.60	15087.60
APPLICATION OF FUNDS :
Gross Block	8899.60	8677.40	7999.80	7685.80	7009.10	6564.20
Less : Accumulated Depreciation	4697.50	4308.00	3815.70	3349.90	2897.10	2455.20
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	4202.10	4369.40	4184.10	4335.90	4112.00	4109.00
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	1188.50	633.90	739.30	384.00	570.50	552.60
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	11491.50	7283.00	4879.30	5118.00	6470.60	6404.10
Current Assets, Loans & Advances
Inventories	1952.10	1687.30	1782.40	1926.30	1780.00	1394.70
Sundry Debtors	8161.80	4740.10	3505.30	2277.70	1903.80	2456.70
Cash and Bank Balance	144.10	414.40	248.10	302.60	154.00	385.30
Loans and Advances	820.20	1069.50	1420.80	2110.30	2193.90	556.00
Total Current Assets	11078.20	7911.30	6956.60	6616.90	6031.70	4792.70
Less : Current Liabilities and Provisions
Current Liabilities	1869.10	1669.20	1539.30	1384.50	1401.70	1195.10
Provisions	504.30	252.80	199.10	105.90	111.00	70.50
Total Current Liabilities & Provisions	2373.40	1922.00	1738.40	1490.40	1512.70	1265.60
Net Current Assets	8704.80	5989.30	5218.20	5126.50	4519.00	3527.10
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	195.70	179.90	112.00	136.60	129.70	92.20
Deferred Tax Liability	341.30	238.20	306.30	289.70	237.00	290.50
Net Deferred Tax	-145.60	-58.30	-194.30	-153.10	-107.30	-198.30
Other Assets	4356.60	3887.20	3804.30	1285.20	1278.80	693.10
Total Assets	29797.90	22104.50	18630.90	16096.50	16843.60	15087.60
Contingent Liabilities	154.00	111.00	319.90	1797.10	1503.90	3690.30

Cash Flow (₹ in cr)

Yearly Cash Flow	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Financing Activities	255.30	-1,709.80	827.00	-300.80	1,384.50
Investing Activities	-2,713.80	768.20	-1,959.30	-1,831.80	-4,503.60
Net Cash Flow	-231.30	369.10	-54.10	-132.30	-5.10
Operating Activities	2,227.20	1,310.70	1,078.20	2,000.30	3,114.00

Peers

Balance Sheet Financial Ratios Profit & Loss

No Data Available!!!

Corporate Actions

Bonus Dividends Splits

Date	Corporate Action	Information
No Corporate Actions Announced

Board of Directors

Chairman & Chief Executive Officer

PRP

Pankaj R Patel

Chairman (Non-Executive)

Executive

Functional Directors

SPP

Sharvil P Patel

Managing Director

MMP

Mukesh M Patel

Non Executive Director

Exec.

GNN

Ganesh N Nayak

Whole-time Director

WTD

Independent Directors

ASD

Apurva S Diwanji

Independent Director

Ind.

BKS

Bhadresh K Shah

Independent Director

Ind.

AAM

Akhil A. Monappa

Independent Director

Ind.

Upasana Konidela.

Independent Director

Ind.

SPP

Shelina P. Parikh

Independent Director

Ind.

Other Officials

DNS

Dhaval N Soni

Company Sec. & Compli. Officer

Board

Frequently Asked Questions

What is the NSE symbol and BSE code for Zydus Lifesciences Ltd? −

Zydus Lifesciences Ltd trades on NSE under ZYDUSLIFE and on BSE under code 532321. The ISIN is INE010B01027 and the face value is Rs 1.

What is the share price of Zydus Lifesciences Ltd today? +

As of 04 July 2026, Zydus Lifesciences Ltd trades at Rs 1,140.60, a change of 40.80 (3.71%) on the day. Prices are live and subject to change.

What is the market capitalisation of Zydus Lifesciences Ltd? +

As of 04 July 2026, Zydus Lifesciences Ltd has a market cap of about Rs 114811.3 crore. This figure is live and moves with the share price.

Is Zydus Lifesciences Ltd profitable? +

In March 2025, Zydus Lifesciences Ltd reported a profit after tax of Rs 4,525.50 crore. The wording switches to "a net loss of Rs X crore" when the figure is negative.

What is the PE ratio of Zydus Lifesciences Ltd? +

: As of 04 July 2026, the PE (TTM) for Zydus Lifesciences Ltd is 31.09 and the price-to-book ratio is 4.85. When the PE shows zero, state that PE TTM is currently not applicable and give the PB only.

Does Zydus Lifesciences Ltd pay a dividend? +

As of 04 July 2026, the dividend yield for Zydus Lifesciences Ltd is 0.09%. The wording switches to "does not currently pay a dividend" when the yield is zero.

What is the shareholding pattern of Zydus Lifesciences Ltd? +

As of the latest disclosed pattern, promoters hold 75.01% of Zydus Lifesciences Ltd. Public shareholding is 24.99%, including mutual funds at 4.92% and foreign institutional investors at 6.89%.

What were the latest annual financials of Zydus Lifesciences Ltd? +

In March 2025, Zydus Lifesciences Ltd reported net sales of Rs 23,241.50 crore, revenue growth of 18.90%, and earnings per share of Rs 44.97.

Invest with clarity

on Chola Securities Mobile & Web App.

Stay organised, informed & in control while accessing your portfolio, reports, trading tools and service requests—all in one seamless platform.

Download the app now → The new app is listed as Chola Securities- Prime Access on App store & Google Play.
Also available on Web, Click to explore